Mafodotin

Mafodotin, referring to monomethyl auristatin F (MMAF) when employed as a cytotoxic payload in antibody–drug conjugates, is used to treat relapsed or refractory multiple myeloma. It serves as the potent toxic component in the ADC belantamab mafodotin (Blenrep), which targets B-cell maturation antigen (BCMA) on myeloma cells. Once internalized, the MMAF disrupts microtubule formation, induces cell cycle arrest, and triggers apoptotic death in malignant cells. The directory classifies it as a unknown/inactive API with a peptide source/manufacturing origin. Other names for this substance include Maleimidocaproyl monomethylauristatin F and Auristatin F derivative. Its PubChem CID is 56949327.

CAS No 863971-19-1
Molecular Formula C49H76N6O11
Molecular Weight 925.20 g/mol
Synonyms (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid

Frequently Asked Questions